About Thrombolytic Science
Thrombolytic Science is a company based in Cambridge (United States) founded in 2006. Thrombolytic Science has raised $7.5 million across 1 funding round. The company has 6 employees. Thrombolytic Science offers products and services including Dual Thrombolytic Regimen. Thrombolytic Science operates in a competitive market with competitors including Basking Biosciences, Acticor Biotech, 4TEEN4 Pharmaceuticals, AptaTargets and CeleCor Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 6
- SectorsHealthcare
- Website tsillc.net
- Social LinkedIn X Facebook
- Legal Name Tsi Inc
- Total Equity Funding$7.5M (USD)
in 1 rounds
- Latest Funding Round$7.5M (USD), Series A
Jan 2012
- Employee Count6
Products & Services of Thrombolytic Science
Thrombolytic Science offers a comprehensive portfolio of products and services, including Dual Thrombolytic Regimen.
Low-dose treatment for dissolving clots in ischemic strokes
Funding Insights of Thrombolytic Science
Thrombolytic Science has successfully raised a total of $7.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.5 million completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.5M
- Total Rounds 1
- Last Round Series A — $7.5M
- First Round $7.5M
(Jan 2012)
All 1 funding rounds of Thrombolytic Science with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2012 | $7.5M | Series A | – | – | – |
Timeline of Thrombolytic Science
2 dated milestones of Thrombolytic Science across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Thrombolytic Science is founded.
- Funding First funding round of $7.5M.
Competitors of Thrombolytic Science
Thrombolytic Science operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Basking Biosciences, Acticor Biotech, 4TEEN4 Pharmaceuticals, AptaTargets and CeleCor Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| baskingbiosciences.com | 2019 | Columbus, United States | $89.8M | 3 | Therapeutics for ischemic stroke treatment are developed. | |
| acticor-biotech.com | 2013 | Paris, France | $31.36M | – | Immunotherapeutics are developed for ischemic stroke treatment using monoclonal antibodies. | |
| 4teen4.de | 2013 | Hennigsdorf, Germany | $30.68M | – | Therapeutics and diagnostics for cardiovascular diseases are developed. | |
| aptatargets.com | 2014 | Madrid, Spain | $2.98M | – | Provider of therapeutic solutions for ischemic diseases | |
| celecor.com | 2017 | San Diego, United States | $46.5M | – | POC subcutaneous injectable for myocardial infarction treatment is developed. | |
| infensabioscience.com | 2021 | Sydney, Australia | $15.6M | – | Peptide drugs for cardiovascular disorders are developed. | |
| f4-pharma.com | 2013 | Vienna, Austria | – | – | Drugs are manufactured to prevent reperfusion injury after myocardial infarction. | |
| endoprotech.com | 2005 | Louisville, United States | – | – | Liposome-based therapies are developed for myocardial infarction and liver disease. | |
| decktherapeutics.com | 2019 | Albany, United States | – | – | Drugs for traumatic brain injury and stroke are developed. |
Detailed competitors of Thrombolytic Science
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Thrombolytic Science
Complete news archive for Thrombolytic Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Thrombolytic Science
10 companies that operate in the same segment as Thrombolytic Science (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | USD 57.22 M | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Thrombolytic Science
Thrombolytic Science was founded in 2006 and raised its 1st funding round 6 years after it was founded.
Thrombolytic Science is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Thrombolytic Science is a funded company, having raised a total of $7.5M across 1 funding round to date. The company's 1st funding round was a Series A of $7.5M, raised on Jan 2012.
Thrombolytic Science has 6 employees.
Thrombolytic Science was established in 2006 in Cambridge, United States, within the vascular medicine sector. Operations center on the creation of thrombolytic treatments for stroke and related thrombotic conditions. A rationally designed mutant of prourokinase, referred to as mproUK, serves as the key component in these clot-dissolving therapies. Development efforts target improved efficacy in addressing vascular blockages.
Thrombolytic Science's top competitors include Acticor Biotech, 4TEEN4 Pharmaceuticals and Basking Biosciences.
Thrombolytic Science offers Dual Thrombolytic Regimen.
Thrombolytic Science operates through Tsi Inc.